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These authors equally contributed to this work.The spread of carbapenemase-producing Klebsiella pneumoniae
(KPC-Kp) has become a worldwide problem in recent years,
with a reported fatality rate from 22% to 72% [1]. In Europe,
outbreaks of KPC-Kp have been reported in several countries,
but data from the European Antimicrobial Resistance Sur-
veillance Network (EARS-Net) surveillance system showed
that, until 2009, the proportion of KPC-Kp remained stable in
most countries except Greece and Italy, where an increase has
been reported from 1–2% in 2006–2009 to 15.2% in 2010,
and 27% in 2011 [1]. This trend has been conﬁrmed by the
Micronet sentinel surveillance network and a recent coun-
trywide cross-sectional survey outlining the epidemic
dissemination in Italy of carbapenem-resistant Enter-
obacteriaceae, mostly related to the clonal diffusion of type A
KPC-Kp of clonal complex 258 [2,3]. More recently, data from
Italian local surveillance systems revealed a persistent condi-
tion of KPC-Kp endemicity in hospitals from the North area
[4]. In this work, we report results of a 1-yearly-basis noso-
comial survey of KPC in North-West Italy, covering theClinical Microbiology and Infection © 2014 European Society of Cmetropolitan area of Turin (2 297 917 inhabitants with ﬁve
tertiary referral centres). Aims were to focus on KPC epide-
miology in hospital wards as well as antibiotic susceptibility
patterns in the year 2012.
The regional surveillance program for infection control in
Piedmont, Italy North-West depends upon the national and the
EARS-Net surveillance systems. It is organized as a network
involving Public Health Infection Control Units from regional
hospitals with a central coordination board. Data collection is
made yearly and involves 29 regional units covering the entire
area (4 374 000 inhabitants, 620 917 hospital admissions, and
4 314 245 hospital days/year) including eight tertiary referral
and 21 secondary care centres, whose mandatory task on a
yearly basis is to report KP and KPC-Kp clinical isolates from
any sample (e.g. urine, blood, sputum, tracheal aspirate, bron-
choalveolar lavage, injury swab, abdominal drainage ﬂuid) to
investigate the local KPC-Kp epidemiology. The data-set
including only non-duplicate clinical isolates and, for each
isolate, site of sampling, antibiotic susceptibility pattern, and
hospital ward. Data referring to KPC-Kp screening from rectal
swabs were not included.
Participating laboratories were asked to provide full infor-
mation on the methods used for KPC-Kp identiﬁcation (e.g.
automated systems) and antibiotic susceptibility. KPC-Kp
showing a pattern of multi-resistance (MIC for meropenem
>0.5 mg/L) was evaluated for carbapenemase production by
meropenem plus EDTA and meropenem plus phenylboronic
acid using the disk diffusion method. MICs to colistin, tigecy-
cline, and gentamicin were conﬁrmed with the E-test (Bio-
Mérieux, Marcy l’Etoile, France).
There were 8179 Klebsiella pneumoniae isolates from
different samples, and 1433 isolates were conﬁrmed as KPC-Kp
(17.5%). Tertiary hospitals accounted for the highest KPC-Kp
absolute number and the highest rate; being in 5/8 signiﬁ-
cantly higher than the average count (49; 13.4%). According to
hospital admissions, average KPC-Kp incidence was 1.9 per
1000, with peaks in 7/8 tertiary hospitals. Overall, there was a
reduction of KPC-Kp incidence per hospital admissions
compared to 2011 (average: 3/1000), which was important in
three tertiary centres (ID# 26T, 23T, and 24T).
The majority of KPC-Kp was isolated from urine (50%),
respiratory samples (22%), and blood (12%). As many as 31% of
KPC-Kp were isolated from patients admitted to medical wards
followed by those in intensive care units (ICU; 15%), emergency
departments (14%), surgical wards (13%,) and long-term facil-
ities (10%). Sample distribution was different according to
wards of admission (Fig. 1): in medical wards, emergency de-
partments and long-term facilities, the majority of KPC-Kp was
urinary (56%, 85%, 84%, respectively), whilst in the ICU thereClin Microbiol Infect 2015; 21: e11–e13
linical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved
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FIG. 1. Carbapenemase-producing Klebsi-
ella pneumoniae (KPC-Kp) samples distribu-
tion according to ward admission. ICU,
intensive care unit.
TABLE 1. Percentage of KPC-Kp susceptibility to colistin,
tigecycline, and gentamycin in participant centres
Hospital ID
Colistin
susceptibility (%)
Tigecycline
susceptibility (%)
Gentamicin
susceptibility (%)
1 100 NA 50
3 82.3 NA 30
4 100 NA 50
5 75 71 50
6 94.6 NA 64.7
8 91.7 6.8 30.6
12 NA NA 52.5
13 90 NA 58.5
14 51.8 92.3 33.3
15 64.3 41.7 35.7
16 95 100 70
18 NA NA 100
19 100 100 83.8
19 NA NA 53.6
20 84.6 NA 54
22 100 100 14
25 NA NA 20
17T 75 NA 62.5
23T 95 NA 49
24T 74.2 57.2 54.5
26T 67 NA 20
27T NA 96.3 38
28T 90 12.5 41.7
2T 98.7 5.5 55.8
9T 87.8 NA 46.3
KPC-Kp, carbapenemase-producing Klebsiella pneumoniae; NA, not applicable; T,
tertiary care centres.
Susceptibility data were available for 25 out of 29 hospital centres (86%).
e12 Clinical Microbiology and Infection, Volume 21 Number 2, February 2015 CMIwere more isolates from the respiratory tract (56%) and blood
(16%). Importantly, KPC-Kppositive blood cultures were found
at a similar rate in ICUs and medical wards (16%).
Antibiotic susceptibility in secondary and tertiary care cen-
tres, respectively, ranged from 75–100% Vs. 67–90% for
colistin, 10–71% Vs. 6–57% for tigecycline, and 50–100%
Vs. 30–55% for gentamicin. Colistin and tigecycline were tested
in only 80% and 44% of laboratories, respectively, mainly in
tertiary hospitals (Table 1).
A rapid dissemination of KPC-Kp has been reported in Italy
since 2010 and conﬁrmed in recently published cross-sectional
surveys, challenging the healthcare system for infection control
and prevention procedures [2]. This is the ﬁrst survey in the
North-West of Italy, covering a wide geographical area
(4 374 000 inhabitants) and conﬁrming KPC-Kp epidemic
diffusion. Our results, in line with those reported from the
Italian national surveillance system (11.9%) and another recent
local report (19.4%), showed that the majority of KPC-Kp was
isolated in the year 2012 from patients admitted to tertiary
referral centres, even if KPC-Kp incidence decreased compared
to the year 2011 in these types of hospitals [2,3]. Tertiary
hospitals accounted for the highest absolute number and rate of
KPC, but our data deﬁnitively show that the KPC-Kp diffusion is
also affecting secondary care hospitals, the incidence of KPC-Kp
being above the regional average in one-third of them, under-
scoring that these data should be considered when planning
infection control strategies. Moreover, our data highlighted a
new trend in KPC-Kp infections, affecting more medical wards
with a high number of urinary colonization in this settingClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectcompared to the ICU, where KPC-Kps were isolated mostly
from respiratory airways and blood, suggesting that KPC-Kp is
no longer a major issue for critically ill patients [5].
In conclusion, encouraging results of this survey conﬁrm a
decreasing trend in KPC-Kp mainly in tertiary referral hospitals.
However, KPC-Kp is becoming a challenge also for secondaryious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21 e11–e13
CMI Letter to the EditorBacteriology e13care hospitals as well as medical wards, conﬁrming that
continuous surveillance is important and that implementation of
infection control measures at both the local and regional levels
is a key issue for success in this advanced phase of the epidemic.
Nowadays, the analysis of susceptibility to colistin and tigecy-
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